Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets Size & Share to 2021 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets Size & Share to 2021

Description:

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. Enquiry @ – PowerPoint PPT presentation

Number of Views:41

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets Size & Share to 2021


1
Non-Small Cell Lung Cancer Therapeutics in Major
Developed Markets to 2021
No. Pages 113
Published on September - 2015
2
.
Report Overview
About Non-Small Cell Lung Cancer Therapeutics in
Major Developed Markets to 2021 Non-Small Cell
Lung Cancer (NSCLC) is the second most common
cancer globally, and the most common cause of
cancer-related mortality. Such a poor outlook,
particularly for patients with advanced disease,
has created a pressing need for improved
therapeutic options. The NSCLC market is
undergoing a gradual change from a focus on
generic chemotherapy regimens to complex
treatment landscape based on different NSCLC
subtypes and the presence of various molecular
aberrations. In the current market, patients with
non-squamous histology can be treated with more
efficacious therapies such as Alimta
(pemetrexed), while patients harboring activating
mutations in EGFR or ALK can be prescribed
targeted therapy. While the NSCLC developmental
pipeline must aim to improve the outlook for all
patients, there is currently a lack of options
for patients with squamous cell histology or
other detectable molecular characteristics
besides EFGR and ALK mutations. Get Full Details
On http//www.researchbeam.com/non-small-cell-lu
ng-cancer-therapeutics-in-major-developed-to-2021-
emergence-of-immunotherapies-drives-growth-and-cre
ates-a-competitive-second-line-market
3
.
Report Overview
Scope The NSCLC market will be valued at 10.9
billion in 2021, growing from 6.1 billion in
2014 at a CAGR of 8.5 - - How will
immunotherapies such as Keytruda affect growth?
- What effect will patent expirations of Tarceva
and Alimta have on market value? The NSCLC
pipeline is large and diverse, with an increased
presence of mAbs and specific targeted therapies
in contrast to the market - - What are the
common targets and mechanisms of action of
pipeline therapies? - Will the pipeline address
unmet needs such as a lack of treatments for
squamous cell patients? - What implications
will the increased focus on targeted therapies
have on the future of NSCLC treatment? Numerous
late-stage pipeline therapies with a strong
clinical record have the potential to enter the
market over the forecast period -
4
.
Report Overview
- How have promising late-stage therapies
performed in clinical trials? - How would the
approval of Rociletinib affect the competitive
landscape? - What is the individual commercial
forecast for each therapy? The market forecasts
indicate that the US contributes the most to
global market value due to a large treatment
population and the high price of premium
therapies. - How will ACoT and market size vary
between the eight major markets? - How could a
change in risk factors such as population age or
smoking habits influence the market? Licensing
deals are the most common form of strategic
alliance in NSCLC, with total deal values ranging
from under 10m to over 1 billion. - How do
deal frequency and value compare between target
families and molecule types? - What were the
terms and conditions of key licensing deals?
Reasons to buy This report will allow you to - -
Understand the current clinical and commercial
landscape by considering disease pathogenesis,
5
Report Overview
  • diagnosis, prognosis, and the treatment options
    available at each stage of diagnosis, including a
    clinical comparison of marketed therapies.
  • Visualize the composition of the NSCLC market in
    terms of dominant therapies for each patient
    subset along with their clinical and commercial
    standing. Unmet needs in the current market are
    highlighted to allow a competitive understanding
    of gaps in the current market.
  • - Analyze the NSCLC pipeline and stratify
    pipeline therapies by stage of development,
    molecule type and molecular target.
  • - Understand the potential of late-stage
    therapies with extensive profiles of products
    that could enter the market over the forecast,
    highlighting clinical performance, potential
    commercial positioning, and how they will compete
    with other therapies.
  • - Predict NSCLC market growth in eight major
    markets with epidemiological and ACoT forecasts
    across the US, Canada, UK, France, Germany,
    Italy, Spain and Japan, as well as individual
    drug contributions to market growth.
  • - Identify commercial opportunities in the NSCLC
    deals landscape by analyzing trends in licensing
    and co-development deals.

6
Table Of Contents
1 Table of Contents 51.1 List of Tables 61.2
List of Figures 72 Introduction 82.1 Disease
Introduction 82.2 Epidemiology 92.3 Etiology
and Pathophysiology 92.3.1 Adenocarcinoma
112.3.2 Squamous Cell Carcinoma 132.3.3 Large
Cell Carcinoma 152.3.4 Immunotherapy 162.4
Symptoms 172.5 Diagnosis 172.6 Prognosis 19
7
Table Of Contents
2.7 Treatment 202.7.1 Treatment Algorithm
212.7.2 First-Line Treatment 212.7.3
Maintenance Therapy 232.7.4 Second-Line
Treatment 242.7.5 Third-Line Therapy 252.7.6
Adjuvant Therapy 252.8 Marketed Product Heatmaps
253 Marketed Products 293.1 Overview 293.2
Chemotherapies 293.3 Alimta - Eli Lilly 293.4
Abraxane - Celgene Corporation 303.5 Tarceva -
Roche 31
8
Table Of Contents
3.6 Iressa - AstraZeneca 323.7 Gilotrif -
Boehringer Ingelheim 333.8 Xalkori - Pfizer
34 3.9 Avastin - Roche 343.10 Cyramza - Eli
Lilly 353.11 Opdivo - Bristol-Myers Squibb
363.12 Zykadia - Novartis 373.13 Alectinib -
Roche 383.14 Conclusion 39Enquiry about this
report _at_ http//www.researchbeam.com/non-small-cel
l-lung-cancer-therapeutics-in-major-developed-to-2
021-emergence-of-immunotherapies-drives-growth-and
-creates-a-competitive-second-line-market/enquire-
about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/non-small-cell-lung-ca
ncer-therapeutics-in-major-developed-to-2021-emerg
ence-of-immunotherapies-drives-growth-and-creates-
a-competitive-second-line-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com